Cargando…
High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate
CD19 and CD21 (CR2) are co-receptors found on B-cells and various B-cell lymphomas, including non-Hodgkin lymphoma. To evaluate their suitability as targets for therapy of such lymphomas using internalization-dependent antibody-drug conjugates [such as antibody-4-(N-maleimidomethyl)cyclohexane-1-car...
Autores principales: | Ingle, Gladys S, Chan, Pamela, Elliott, J Michael, Chang, Wesley S, Koeppen, Hartmut, Stephan, Jean-Philippe, Scales, Suzie J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228374/ https://www.ncbi.nlm.nih.gov/pubmed/17991300 http://dx.doi.org/10.1111/j.1365-2141.2007.06883.x |
Ejemplares similares
-
Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells
por: Fuh, Franklin K, et al.
Publicado: (2017) -
CD8+CD39+ T Cells Mediate Anti-Tumor Cytotoxicity in Bladder Cancer
por: Zhu, Wenjie, et al.
Publicado: (2021) -
Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells
por: Ruella, Marco, et al.
Publicado: (2015) -
Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
por: Tabbara, Nadeem, et al.
Publicado: (2021) -
Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies
por: Luanpitpong, Sudjit, et al.
Publicado: (2021)